In Europe, Science has applied for regulatory approval and hopes to have PRIMA available to patients later this year. In the United States, a Food and Drug Administration approval process is underway.

Diseases that affect the retina, the light-sensitive layer at the back of the eye, are a significant cause of visual impairment and blindness. Gene therapy holds promise for treating some of these ...